title: Reply from Authors re: Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We Moving Forward? Eur Urol 2016;69:201-2: The Goal: Individualized Bacillus Calmette-Guérin Therapy.
authors.affiliation: Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org.
authors.forename: Ashish M
authors.initials: AM
authors.lastname: Kamat
authors.affiliation: Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Diana L
authors.initials: DL
authors.lastname: Urbauer
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000627:therapeutic use; D001407:Bacillus; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D006040:Goals; D006801:Humans; D007167:Immunotherapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine